<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317135</url>
  </required_header>
  <id_info>
    <org_study_id>759346/004</org_study_id>
    <nct_id>NCT00317135</nct_id>
  </id_info>
  <brief_title>Safety Study of a Vaccine Against Meningitis in Infants ( 2,4 &amp; 6 Months Age) After a Birth Dose of Hepatitis B.</brief_title>
  <official_title>Assess Reactogenicity &amp; Safety of GSK Biologicals' Tritanrix™-HepB/Hib-MenAC Compared to Tritanrix™-HepB/Hiberix™ (Control) in Healthy Infants (2,4,6 Mths Age), After a Hepatitis B Birth Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the reactogenicity &amp; safety of
      Tritanrix™-HepB/Hib-MenAC vaccine to the international standard of care,
      Tritanrix™-HepB/Hiberix™.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Randomized study with four groups to receive one of the following vaccination regimens after
      a dose of hepatitis B vaccine given at birth:

      - One of the 3 lots of GSK Biologicals' Hib-MenAC mixed with GSK Biologicals' Tritanrix™-HepB
      (3 different groups) - GSK Biologicals' Tritanrix™-HepB/Hiberix™
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2003</start_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 0-3 after each dose, fever &gt;38.5°C(axillary).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Solicited events other than fever (day 0-3); unsolicited events (day 0-30); serious adverse events (entire study).</measure>
  </secondary_outcome>
  <enrollment>500</enrollment>
  <condition>Hib Disease</condition>
  <condition>Hepatitis B</condition>
  <condition>Diphtheria</condition>
  <condition>Pertussis</condition>
  <condition>Neisseria Meningitidis Serogroup Diseases</condition>
  <condition>Tetanus</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DTPw-HBV/Hib-MenAC conjugate vaccine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria at study entry:

          -  Healthy infants aged less than or equal to 3 days of age, written informed consent
             obtained from the parents, born after a gestation period of 36 to 42 weeks.

        Exclusion criteria at study entry:

          -  Any confirmed immunodeficient condition, based on medical history &amp; physical
             examination.

          -  A family history of congenital or hereditary immunodeficiency.

          -  Major congenital defects or serious chronic illness.

          -  History of any neurologic disorders or seizures.

          -  Administration of immunoglobulins and/or any blood products since birth or planned
             administration during the study period.

          -  Acute disease at the time of enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Days</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muntinlupa</city>
        <zip>1781</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Philippines</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 15, 2006</study_first_submitted>
  <study_first_submitted_qc>April 20, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 24, 2006</study_first_posted>
  <last_update_submitted>September 29, 2011</last_update_submitted>
  <last_update_submitted_qc>September 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 3, 2011</last_update_posted>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Diphtheria</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

